Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics, Inc. (KYMR)
:KYMR
KYMR Analyst Ratings
Strong Buy
19 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KYMR Stock 12 Month Forecast
Average Price Target
$67.59
▲(11.08% Upside)
| Highest Price Target$88.00 | Average Price Target$67.59 | Lowest Price Target$53.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Morgan Stanley
$70
Buy
15.04%
Upside
Reiterated
10/27/25
Kymera Therapeutics' KT-579 Shows Promising Preclinical Results, Earning Buy Rating from AnalystWe present key highlights below: For data presented on Lupus models, Kymera included new preclinical data highlighting early, sustained reductions in anti-dsDNA antibodies for treatment with KT-579 across two dose levels vs. other treatments, demonstrating a stronger reduction in anti-dsDNA Abs. Data on KT-579 decreasing pathogenic autoantibodies producing B cell subsets in the spleen of MRL/lpr mice and IgG, C3 and renal disease progression were also highlighted. Finally, a figure demonstrating inhibition of key interferon genes with treatment of KT-579 was also presented in NZB.W1 mice.
Citi
$80
Buy
31.47%
Upside
Assigned
10/24/25
BTIG
$59→$75
Buy
23.25%
Upside
Reiterated
10/22/25
Leerink Partners
$62→$70
Buy
15.04%
Upside
Reiterated
10/17/25
Piper Sandler
$59
Buy
-3.04%
Downside
Reiterated
10/16/25
J.P. Morgan
―
Buy
―
Reiterated
10/08/25
Stifel Nicolaus
$68
Buy
11.75%
Upside
Reiterated
10/07/25
Oppenheimer
$53→$63
Buy
3.53%
Upside
Reiterated
10/01/25
Truist Financial
$53→$68
Buy
11.75%
Upside
Reiterated
09/30/25
H.C. Wainwright
$60→$70
Buy
15.04%
Upside
Reiterated
09/18/25
Barclays
$60
Buy
-1.40%
Downside
Initiated
09/16/25
RBC Capital
$70
Buy
15.04%
Upside
Initiated
09/16/25
Bank of America Securities
$54
Buy
-11.26%
Downside
Reiterated
09/15/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
$70
Buy
15.04%
Upside
Reiterated
10/27/25
Kymera Therapeutics' KT-579 Shows Promising Preclinical Results, Earning Buy Rating from AnalystWe present key highlights below: For data presented on Lupus models, Kymera included new preclinical data highlighting early, sustained reductions in anti-dsDNA antibodies for treatment with KT-579 across two dose levels vs. other treatments, demonstrating a stronger reduction in anti-dsDNA Abs. Data on KT-579 decreasing pathogenic autoantibodies producing B cell subsets in the spleen of MRL/lpr mice and IgG, C3 and renal disease progression were also highlighted. Finally, a figure demonstrating inhibition of key interferon genes with treatment of KT-579 was also presented in NZB.W1 mice.
Citi
$80
Buy
31.47%
Upside
Assigned
10/24/25
BTIG
$59→$75
Buy
23.25%
Upside
Reiterated
10/22/25
Leerink Partners
$62→$70
Buy
15.04%
Upside
Reiterated
10/17/25
Piper Sandler
$59
Buy
-3.04%
Downside
Reiterated
10/16/25
J.P. Morgan
―
Buy
―
Reiterated
10/08/25
Stifel Nicolaus
$68
Buy
11.75%
Upside
Reiterated
10/07/25
Oppenheimer
$53→$63
Buy
3.53%
Upside
Reiterated
10/01/25
Truist Financial
$53→$68
Buy
11.75%
Upside
Reiterated
09/30/25
H.C. Wainwright
$60→$70
Buy
15.04%
Upside
Reiterated
09/18/25
Barclays
$60
Buy
-1.40%
Downside
Initiated
09/16/25
RBC Capital
$70
Buy
15.04%
Upside
Initiated
09/16/25
Bank of America Securities
$54
Buy
-11.26%
Downside
Reiterated
09/15/25
Best Analysts Covering Kymera Therapeutics
1 Month
xxx
Success Rate
7/10 ratings generated profit
Average Return
+6.36%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +6.36% per trade.
3 Months
xxx
Success Rate
7/10 ratings generated profit
Average Return
+8.99%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +8.99% per trade.
1 Year
Success Rate
12/14 ratings generated profit
Average Return
+52.89%
reiterated a buy rating 30 days ago
Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +52.89% per trade.
2 Years
xxx
Success Rate
14/14 ratings generated profit
Average Return
+88.65%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +88.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KYMR Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
13
14
13
9
8
Buy
26
27
31
16
18
Hold
16
12
11
8
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
55
53
55
33
34
Each month's total comprises the sum of three months' worth of ratings.
KYMR Financial Forecast
KYMR Stock Forecast FAQ
What is KYMR’s average 12-month price target, according to analysts?
Based on analyst ratings, Kymera Therapeutics, Inc.’s 12-month average price target is 67.59.
What is KYMR’s upside potential, based on the analysts’ average price target?
Kymera Therapeutics, Inc. has 11.08% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KYMR a Buy, Sell or Hold?
Kymera Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 19 buy ratings, 0 hold ratings and 0 sell ratings.
What is Kymera Therapeutics, Inc.’s price target?
The average price target for Kymera Therapeutics, Inc. is 67.59. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $88.00 ,the lowest forecast is $53.00. The average price target represents 11.08% Increase from the current price of $60.85.
The highest analyst price target is $88.00 ,the lowest forecast is $53.00. The average price target represents 11.08% Increase from the current price of $60.85.
What do analysts say about Kymera Therapeutics, Inc.?
Kymera Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 19 Wall Streets Analysts.
How can I buy shares of KYMR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.